TargetMol

Angiotensin III, human, mouse

Product Code:
 
TAR-T7577
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T7577-10mg10mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7577-25mg25mg£144.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7577-50mg50mg£193.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7577-100mg100mg£270.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7577-200mg200mg£372.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Angiotensin III, human, mouse(3TFA) is an endogenous angiotensin II receptor (AT2R) agonist(IC50s of 0.648 nM).
CAS:
13602-53-4
Formula:
C46H66N12O9
Molecular Weight:
931.109
Pathway:
Endocrinology/Hormones
Purity:
1
SMILES:
CCC(C)C(NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(NC(=O)C(N)CCCN=C(N)N)C(C)C)C(=O)NC(Cc1cnc[nH]1)C(=O)N1CCCC1C(=O)NC(Cc1ccccc1)C(O)=O
Target:
RAAS

References

Kemp B A , Bell J F , Rottkamp D M , et al. Intrarenal Angiotensin III Is the Predominant Agonist for Proximal Tubule Angiotensin Type 2 Receptors[J]. Hypertension, 2012, 60(2):387-395. Bosnyak S , Jones E S , Christopoulos A , et al. Relative affinity of angiotensin peptides and novel ligands at AT(1) and AT(2) receptors[J]. Clinical Science, 2011, 121(7):297-303.